PRE-LAUNCH · EARLY ACCESS
Built for the signals that fall
through the cracks of an 8,000-ticker terminal.
Dilution detection wired into the FDA catalyst calendar. Insider buying cross-checked against rising short interest. Filings translated into plain English — across a deliberately curated universe of 287 biotech names.
No spam · invites in waves · not investment advice
Every terminal races to cover 8,000 tickers.
We chose 287.
Coverage is a vanity metric. The moment a tool tries to watch everything, it watches nothing well. BioVista tracks a deliberately curated universe of clinical-stage and commercial biotech — deeply — so every signal actually means something.
Smaller and accurate beats large and wrong.
≈ 1 in 28 public biotechs makes the cut. The rest is noise we deliberately leave out.
Three signals you won't find
fused anywhere else.
Get in before launch.
Join the early-access list. Early subscribers get in first, lock early pricing, and shape what we track early on.
No spam · invites in waves · not investment advice